Japan Pain Management Drugs Market - Strategic Insights and Forecasts (2025-2030)

Japan pain management drugs market analysis focusing on non-opioid alternatives, regulatory frameworks, and evolving prescription patterns in clinical practice.

$2,850

Single User License

Access Full Insights

Report Overview

Japan pain management drugs market is anticipated to grow at a CAGR of 2.98% from 2025 to 2030.

Japan Pain Management Drugs Highlights

Aging population growing rapidly

Seniors are experiencing more age-related chronic pain conditions daily.

Chronic pain cases rising steadily

Millions of residents are seeking effective relief for persistent discomfort.

Cancer patients requiring better control

Individuals are managing treatment-related pain with advanced pharmacological options.

Healthcare access expanding nationwide

Government initiatives are improving the availability of pain relief drugs in rural areas.

OTC sales progressing quickly

Consumers are increasingly purchasing over-the-counter analgesics for everyday pain management.

Japan Pain Management Drugs Market Trends:

The market growth is majorly attributed to the rising geriatric population in Japan, and low fertility rates, coupled with improving life expectancy on account of improving nutrition, low prevalence of diseases, and availability of state-of-the-art medical and pharmacological technologies in the country, which is increasing the number of older people.

According to the “Statistical Handbook of Japan 2024”, issued by the Ministry of Internal Affairs and Communication, by 2050, the population aged 65 years and above will account for 38.7% of the total population. Likewise, as per the “Annual Report on Annual Society FY2024”, as of October 2023, the population aged 74 years and above was 20.08 million and accounted for 16.1% of the total population.

Besides the growing old-age population, the chronic disease prevalence in Japan has also shown constant growth over the years, which is also anticipated to drive the demand for pain management drugs as they assist in refracting pain. According to the Global Cancer Observatory, in 2022, nearly 1,005,157 new cancer cases were reported in Japan, and the number of deaths reached 426,278. Hence, the same source also stated that prostate, lung, and stomach-related cancer cases were most commonly reported.

Moreover, the favorable policies and schemes by the Japanese government to increase healthcare access to rural societies, followed by progression in over-the-counter drug sales, have provided new growth prospects for the pain management drugs market in Japan. Likewise, various key market players, namely Shionogi Inc. and Daiichi Sankyo, have well-established customer bases in Japan, and the companies are forming strategic collaborations with global firms such as Pfizer Inc. to improve their product offering, which is estimated to stimulate the market growth.

Japan Pain Management Drugs Market Scope:

Report Metric	Details
Forecast Unit	Billion
Growth Rate	2.98%
Study Period	2020 to 2030
Historical Data	2020 to 2023
Base Year	2024
Forecast Period	2025 – 2030
Segmentation	Drug Type, Distribution Channel, Indication, City
Geographical Segmentation	Tokyo, Yokohama, Osaka, Nagoya, Others
Companies	Novartis Pharmaceuticals Corporation (Novartis AG) Eli Lilly and Company Pfizer Inc. GlaxoSmithKline plc Sanofi S.A Johnson & Johnson Viatris Inc. DAIICHI SANKYO COMPANY LIMITED Shionogi Inc. Asahi Kasei Pharma Corporation

Market Segmentation

By Drug Type

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

Corticosteroids

Acetaminophen

Opioid

Strong Opioid

Weak Opioid

Antidepressants

Anticonvulsant Drugs

Others

By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By Indication

Cancer

Rheumatoid Arthritis

Chronic Back Pain

Post-Operative Pain

Others

By City

Tokyo

Yokohama

Osaka

Nagoya

Others

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

2.1. Market Overview

2.2. Market Definition

2.3. Scope of the Study

2.4. Market Segmentation

3. BUSINESS LANDSCAPE

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities

3.4. Porter’s Five Forces Analysis

3.5. Industry Value Chain Analysis

3.6. Policies and Regulations

3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. JAPAN PAIN MANAGEMENT DRUGS MARKET BY DRUG TYPE

5.1. Introduction

5.2. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

5.3. Corticosteroids

5.4. Acetaminophen

5.5. Opioid

5.5.1. Strong Opioid

5.5.2. Weak Opioid

5.6. Antidepressants

5.7. Anticonvulsant Drugs

5.8. Others

6. JAPAN PAIN MANAGEMENT DRUGS MARKET BY DISTRIBUTION CHANNEL

6.1. Introduction

6.2. Hospital Pharmacies

6.3. Retail Pharmacies

6.4. Online Pharmacies

7. JAPAN PAIN MANAGEMENT DRUGS MARKET BY INDICATION

7.1. Introduction

7.2. Cancer

7.3. Rheumatoid Arthritis

7.4. Chronic Back Pain

7.5. Post-Operative Pain

7.6. Others

8. JAPAN PAIN MANAGEMENT DRUGS MARKET BY CITY

8.1. Introduction

8.2. Tokyo

8.2.1. By Drug Type

8.2.2. By Distribution Channel

8.2.3. By Indication

8.3. Yokohama

8.3.1. By Drug Type

8.3.2. By Distribution Channel

8.3.3. By Indication

8.4. Osaka

8.4.1. By Drug Type

8.4.2. By Distribution Channel

8.4.3. By Indication

8.5. Nagoya

8.5.1. By Drug Type

8.5.2. By Distribution Channel

8.5.3. By Indication

8.6. Others

8.6.1. By Drug Type

8.6.2. By Distribution Channel

8.6.3. By Indication

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Competitive Dashboard

10. COMPANY PROFILES

10.1. Novartis Pharmaceuticals Corporation (Novartis AG)

10.2. Eli Lilly and Company

10.3. Pfizer Inc.

10.4. GlaxoSmithKline plc

10.5. Sanofi S.A

10.6. Johnson & Johnson

10.7. Viatris Inc.

10.8. DAIICHI SANKYO COMPANY, LIMITED

10.9. Shionogi Inc.

10.10. Asahi Kasei Pharma Corporation.

11. APPENDIX

11.1. Currency

11.2. Assumptions

11.3. Base and Forecast Years Timeline

11.4. Key benefits for the stakeholders

11.5. Research Methodology

11.6. Abbreviations

Request Customization

Tell us your specific requirements and we will customize this report for you.

Download Free Sample

Get a sample copy of this report with charts, TOC, and methodology.

Speak to Analyst

Ask our analysts any questions you have about this market research report.

Japan Pain Management Drugs Market Report

Report IDKSI061617517

PublishedJun 2025

Pages87

FormatPDF, Excel, PPT, Dashboard

⬇️ Download Free Sample

📞 Speak to Analyst

Need Assistance?

Our research team is available to answer your questions.

Frequently Asked Questions

The Japan Pain Management Drugs Market is anticipated to grow at a CAGR of 2.98% from 2025 to 2030. This growth is primarily attributed to the rising geriatric population, increasing prevalence of chronic pain conditions, and expanding healthcare access across the nation.

The market's growth is largely driven by Japan's rapidly aging population and improving life expectancy. The report highlights that the population aged 65 years and above is projected to account for 38.7% of the total by 2050, with seniors experiencing more age-related chronic pain conditions daily, thereby increasing the demand for pain management drugs.

Demand for pain management drugs in Japan is significantly driven by a rising prevalence of chronic diseases, particularly cancer and rheumatoid arthritis. In 2022, nearly 1,005,157 new cancer cases were reported in Japan, leading to an increased need for effective pain control. The market also addresses chronic back pain and post-operative pain.

Yes, the market is experiencing significant progression in over-the-counter (OTC) drug sales, with consumers increasingly purchasing analgesics for everyday pain management. Additionally, favorable government policies are expanding healthcare access to rural societies, improving the availability of pain relief drugs through various distribution channels, including hospital, retail, and online pharmacies.

Key market players mentioned include Shionogi Inc. and Daiichi Sankyo, which possess well-established customer bases in Japan. These companies are actively forming strategic collaborations with global firms such as Pfizer Inc. to improve their product offerings and stimulate overall market growth in the country.

Yes, the report's scope explicitly includes analysis and forecasts 'By City' from 2025 to 2030, indicating a detailed geographical breakdown. While specific city-level data is not detailed in the provided excerpt, the report highlights government initiatives aimed at improving healthcare access and drug availability in rural areas nationwide, suggesting a comprehensive regional outlook within the full analysis.

Need data specifically for your business?Request Custom Research →

Related Reports